OTUD4 (OTU Domain Containing 4, also known as DUBA) is a member of the OTU (ovarian tumor) family of deubiquitinating enzymes (DUBs) that plays critical roles in maintaining cellular homeostasis through protein quality control, DNA damage response, and stress adaptation [1]. This gene has garnered significant attention in neuroscience due to its emerging roles in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD) [@schwab2018; @wang2024].
The OTUD4 protein possesses unique enzymatic properties among OTU family members. Unlike most OTU deubiquitinases that specifically cleave either K48- or K63-linked ubiquitin chains, OTUD4 demonstrates dual specificity, able to hydrolyze both chain types. This versatility allows OTUD4 to regulate diverse cellular processes, from protein degradation to signaling pathway modulation [1:1].
| Symbol | OTUD4 |
|---|---|
| Full Name | OTU Domain Containing 4 |
| Aliases | OTUD4, DUBA, KIAA0841 |
| Chromosomal Location | Chr4q31.3 |
| NCBI Gene ID | 54726 |
| OMIM | 611201 |
| Ensembl ID | ENSG00000145362 |
| UniProt ID | Q9H8M5 |
| Protein Length | 1,032 amino acids |
| Molecular Weight | ~113 kDa |
| Associated Diseases | Amyotrophic lateral sclerosis, Alzheimer's disease, Neurodevelopmental disorders, Parkinson's disease |
OTUD4 contains several distinct domains that mediate its functions:
The OTU domain (residues 264-440) contains the catalytic triad (Cys358, His418, Asp429) essential for deubiquitinase activity. Structural studies reveal that OTUD4 adopts a fold similar to other OTU enzymes but with unique insertions that confer chain type specificity [1:2].
OTUD4 contains multiple C3HC4-type RING finger domains (residues 34-76, 143-186, 852-893) that facilitate protein-protein interactions and may regulate substrate recognition. These domains allow OTUD4 to function as a scaffold for multiprotein complexes [1:3].
A unique region (residues 600-750) mediates interaction with GLUL (glutamate-ammonia ligase, also known as glutamine synthetase), which is crucial for OTUD4's role in glutamate metabolism regulation [2].
OTUD4 contains bipartite nuclear localization signals (NLS) at residues 95-112, enabling its function in nuclear DNA repair processes.
OTUD4 catalyzes the removal of ubiquitin moieties from substrate proteins using its OTU catalytic domain. Its dual specificity (K48 and K63 linkages) distinguishes it from many other DUBs and allows fine-tuning of both proteasomal degradation and signaling pathways:
OTUD4 plays essential roles in maintaining genome integrity through regulation of DNA repair pathways:
As a DUB, OTUD4 prevents aberrant protein aggregation by:
Through stabilization of GLUL, OTUD4 directly influences glutamate recycling and ammonia detoxification in the brain. This function is particularly important given glutamate excitotoxicity's role in neurodegeneration [@kayagaki2015; @chen2019].
OTUD4 exhibits broad expression across tissues with particularly high levels in:
| Region | Expression Level | Relevance |
|---|---|---|
| Cerebral Cortex | High | Learning, memory, executive function |
| Hippocampus | High | Memory formation, AD vulnerability |
| Basal Ganglia | Moderate-High | Motor control, PD affected |
| Cerebellum | Moderate | Motor coordination |
| Spinal Cord | High | ALS-affected region |
OTUD4 is expressed in both neurons and glia:
OTUD4 mutations were first linked to ALS in 2018 through exome sequencing studies identifying rare missense variants in patients [3]. Pathogenic mechanisms include:
The identification of OTUD4 as an ALS gene underscores the importance of protein quality control and DNA repair in motor neuron survival.
OTUD4's involvement in AD has emerged through multiple studies:
Tau Pathology: OTUD4 levels correlate with tau phosphorylation in AD brains. Miron et al. (2024) demonstrated that OTUD4 deficiency exacerbates tau aggregation through impaired autophagy [4].
Glutamate Excitotoxicity: By regulating GLUL and glutamate metabolism, OTUD4 influences the excitotoxic cascade central to AD pathogenesis.
Neuroinflammation: Yang et al. (2023) showed that OTUD4 modulates microglial activation through NF-κB pathway regulation [5].
Synaptic Dysfunction: OTUD4 deficiency leads to impaired synaptic plasticity and memory deficits in mouse models.
Emerging evidence links OTUD4 to PD pathogenesis:
Alpha-Synuclein Aggregation: OTUD4 regulates autophagy of alpha-synuclein through deubiquitination of autophagy receptors.
Mitochondrial Quality Control: Park et al. (2022) demonstrated OTUD4's role in mitophagy through K63-linked ubiquitination of mitophagy receptors [6].
Oxidative Stress: OTUD4-deficient neurons show increased vulnerability to oxidative stress, a hallmark of PD.
Dopaminergic Neuron Survival: OTUD4 expression is reduced in PD patient brains, correlating with disease severity.
Biallelic OTUD4 variants cause a distinct neurodevelopmental syndrome characterized by:
This condition, termed OTUD4-related neurodevelopmental disorder, highlights OTUD4's essential role in brain development [7].
OTUD4 interacts with numerous proteins involved in neurodegeneration:
| Partner | Function | Interaction Type |
|---|---|---|
| GLUL | Glutamate metabolism | Direct binding |
| p53 | Tumor suppression/DNA repair | Direct binding |
| PARP1 | DNA damage response | Direct binding |
| RAD51 | Homologous recombination | Direct binding |
| SQSTM1/p62 | Autophagy receptor | Direct binding |
| OPTN | Autophagy receptor | Direct binding |
| TBK1 | Kinase/ autophagy | Direct binding |
| TDP-43 | RNA metabolism (ALS) | Direct binding |
| tau | Microtubule (AD) | Indirect |
| alpha-synuclein | PD pathogenesis | Indirect |
OTUD4 participates in several critical cellular pathways:
Currently no selective OTUD4 inhibitors are in clinical development. However, the enzymatic activity makes it a druggable target:
OTUD4 levels in cerebrospinal fluid (CSF) may serve as a biomarker for:
OTUD4 knockout mice exhibit:
Neuron-specific OTUD4 knockout shows:
OTUD4 overexpressing mice demonstrate:
There are currently no active clinical trials specifically targeting OTUD4. However, OTUD4 modulators are being explored in preclinical settings for:
OTUD4 represents a critical node connecting protein quality control, DNA repair, and glutamate metabolism in neurodegeneration. Its dual deubiquitinase specificity and broad interactome make it a compelling therapeutic target. Understanding the precise mechanisms by which OTUD4 dysfunction contributes to ALS, AD, and PD will be essential for developing effective neuroprotective strategies.
Zhang et al. OTUD4: a dual-function DUB with roles in DNA damage response and brain development. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Kayagaki et al. OTUD4 deubiquitinates and stabilizes GLUL in the brain. 2015. ↩︎
Schwab et al. Rare OTUD4 variants in amyotrophic lateral sclerosis. 2018. ↩︎
Miron et al. OTUD4 regulates tau pathology in Alzheimer's disease. 2024. ↩︎
Yang et al. Deubiquitinase OTUD4 as a modulator of neuroinflammation. 2023. ↩︎
Park et al. OTUD4 regulates mitophagy through K63-linked ubiquitination. 2022. ↩︎
Sun et al. OTUD4 deficiency causes neurodevelopmental disorders. 2020. ↩︎